lewil therapy LLC

273 medea way
central islip, new york 11722

NYS Entity Status
INACTIVE - Dissolution (May 15, 2014)

NYS Filing Date
DECEMBER 12, 2013

NYS DOS ID#
4500031

County
NEW YORK

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY

Name History
2013 - LEWIL THERAPY LLC









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • The Gang Murders in the Suburbs
    By LIZ ROBBINS and NADIA T. RODRIGUEZ - Wednesday Jul 12, 2017

    Four young Latino men went to hang out in the woods on Long Island one night during spring break. They ended up victims of the brutal gang MS-13.

    Source: NYT > Home Page
  • In a ‘Summer of Hell,’ Grand Central May Be a Bit of Heaven
    By DAVID W. DUNLAP - Wednesday Jul 5, 2017

    Amtrak will temporarily restore some intercity service to Grand Central Terminal to relieve pressure on the beleaguered Pennsylvania Station.

    Source: NYT > Home Page
  • Christopher Columbus Statue in Central Park Is Vandalized
    By SARAH MASLIN NIR and JEFFERY C. MAYS - Tuesday Sep 12, 2017

    An 1892 bronze statue of Columbus was found covered with graffiti, its hands painted red.

    Source: NYT > Home Page
  • The Look: New York City Parks in the Summer: Romance, Games and a Performance for a Dying Tree
    By DANIEL ARNOLD, JOANNA NIKAS and EVE LYONS - Saturday Sep 2, 2017

    Daniel Arnold spent the last two months photographing parks in all five boroughs. The experience showed him “a very different pulse of the city.”

    Source: NYT > Home Page
  • Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
    By Ben Fidler - Tuesday Sep 12, 2017

    Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]

    Source: Xconomy VC, Deals, & Startups Feed